Publications by authors named "R O Escarcega"

Article Synopsis
  • Alzheimer's disease (AD) is more prevalent in women than in men, with factors beyond longevity, like metabolic changes, influencing this increased risk.
  • A study conducted metabolomic profiling of blood samples from male and female patients with mild cognitive impairment (MCI), revealing significant metabolic differences related to sex, particularly in lipid and peptide energy metabolism pathways.
  • The research identified specific metabolites unique to each sex, such as higher levels of 1-palmitoleoyl glycerol in females, suggesting these could be potential biomarkers to enhance our understanding of MCI and AD prevention strategies.
View Article and Find Full Text PDF
Article Synopsis
  • Rheumatic heart disease (RHD) poses significant health issues, especially in low- and middle-income countries, but data on its impact in wealthier regions like the USA and EU is limited.
  • A study comparing the epidemiology of RHD in the USA and EU revealed that the USA has a higher prevalence (123.4/100,000) but a slower decreasing trend compared to the EU (49.7/100,000), with key trends driven by states like Florida and Tennessee.
  • Both regions show a gender disparity with higher cases in females, and the findings highlight the need for tailored strategies to tackle RHD effectively based on regional data.
View Article and Find Full Text PDF

Alzheimer's disease (AD) affects more women than men. Although women live longer than men, it is not longevity alone, but other factors, including metabolic changes, that contribute to the higher risk of AD in women. Metabolic pathways have been implicated in AD progression, but studies to date examined targeted pathways, leaving many metabolites unmeasured.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs.

View Article and Find Full Text PDF